Mazdutide Phase 2 trial (NCT06124807)
A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 179
- actual
- Start
- 17 Nov 2023 (actual)
- Primary completion
- 22 Jan 2025 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 3/6 Milligrams (mg) Mazdutide | Experimental | Drug: Mazdutide | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (3 or 6 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-31, then 6 mg from Weeks 32-48. |
| 10 mg Mazdutide | Experimental | Drug: Mazdutide | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (10 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 8 mg from Weeks 12-15, and then 10 mg from Weeks 16-48. |
| 16 mg Mazdutide | Experimental | Drug: Mazdutide | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (16 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 9 mg from Weeks 12-15, 12 mg from Weeks 16-19, and then16 mg from Weeks 20-48. |
| Placebo | Placebo comparator | Drug: Placebo | Participants received Mazdutide matched placebo subcutaneously once weekly from Weeks 0 to 48. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight at Week 32 | Baseline, Week 32 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 |
| Change From Baseline in Body Weight | Baseline, Week 32, Week 48 |
| Mean Percentage of Participants Who Achieve ≥5% Body Weight Reduction | Baseline, Week 32, Week 48 |
| Mean Percentage of Participants Who Achieve ≥10% Body Weight Reduction | Baseline, Week 32, Week 48 |
| Change From Baseline in Body Mass Index (BMI) | Baseline, Week 32, Week 48 |
| Number of Participants With Treatment Emergent Anti-drug Antibodies (TE-ADAs) | Baseline up to week 56 |
| Pharmacokinetics (PK): Area Under the Curve (AUC) of Mazdutide at Steady State | Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 32, Week 48; Post dose (2 to 6 hours after dosing) at Week 0, Week 12, Week 24 |
| PK: Maximum Concentration (Cmax) of Mazdutide at Steady State | Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 32, Week 48; Post dose (2 to 6 hours after dosing) at Week 0, Week 12, Week 24 |
| Change From Baseline in Liver Fat Content (LFC) by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) in Participants With Baseline LFC >=5% | Baseline, Week 32, Week 48 |
| Percent Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=5% | Baseline, Week 32, Week 48 |
| Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=10% | Baseline, Week 32, Week 48 |
| Percent Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=10% | Baseline, Week 32, Week 48 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT06124807.
The US dose-range trial of mazdutide up to 16 mg
Adults without type 2 diabetes were randomised 3:2:3:3 to placebo or mazdutide at 3-6 mg, 10 mg or 16 mg weekly for 48 weeks.[2]
At 32 weeks bodyweight changed by -7.3%, -15.6% and -18.1% across the three mazdutide groups, against -0.9% with placebo.[2]
Discontinuation because of adverse events was most frequent on 16 mg, at 20%, mainly for gastrointestinal disorders.[2]
The 3-6 mg group stayed on 3 mg from week 4 to week 32 before escalating to 6 mg, to test 3 mg and 6 mg as maintenance doses.[2]
Sources
- 1A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
Found an error? Report a correction.